Madhup Rastogi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Madhup Rastogi has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Ajeet Kumar Gandhi
Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
5 shared publications - Satyajeet Rath
Department of Radiation Oncology, All India Institute of Medical Sciences, Rajkot, Gujarat, India
5 shared publications Harikesh Bahadur Singh
Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
3 shared publications- Rohini Khurana
Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
3 shared publications Sambit Swarup Nanda
Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
3 shared publications- Swaroop Revannasiddaiah
Department of Radiotherapy, Government Medical College, Haldwani, India
3 shared publications
Latest Publications
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400349
Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA)
PURPOSE: Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs. MATERIALS AND METHODS: A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023. RESULTS: Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on. CONCLUSION: The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400349
Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA)
PURPOSE: Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs. MATERIALS AND METHODS: A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023. RESULTS: Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on. CONCLUSION: The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.
- 4 August 2023
- Published by Elsevier
- p. 323-325
Crossover study
- Open Access
- 12 August 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (3) , 1501-1507
Effect of Chemo-radiotherapy on Salivary Flora of Oral Cancer Patients
- 12 August 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (3) , 1501-1507
Open AccessEffect of Chemo-radiotherapy on Salivary Flora of Oral Cancer Patients
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , e819-e820
A Single Institutional Retrospective Analysis Of 116 Patients Of Post-Operative Buccal Mucosa Cancers Treated With Ipsilateral Radiotherapy Analyzing Predictors Of Failure
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , e819-e820
A Single Institutional Retrospective Analysis Of 116 Patients Of Post-Operative Buccal Mucosa Cancers Treated With Ipsilateral Radiotherapy Analyzing Predictors Of Failure
- Open Access
- 29 September 2020
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 14 (3) , 2129-2135
Alteration in Oral Flora and Effect of Mucositis in Head and Neck Cancer Patients Undergoing Chemo-radiotherapy
- 29 September 2020
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 14 (3) , 2129-2135
Open AccessAlteration in Oral Flora and Effect of Mucositis in Head and Neck Cancer Patients Undergoing Chemo-radiotherapy
- Open Access
- 1 September 2020
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 14 (9)
Cavernous Sinus Metastasis from Carcinoma of Buccal Mucosa- A Rare Case Report and Review of Literature
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
- 1 September 2020
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 14 (9)
Open AccessCavernous Sinus Metastasis from Carcinoma of Buccal Mucosa- A Rare Case Report and Review of Literature
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
- 1 January 2019
- Published by Medknow in Oncology Journal of India
- Vol. 3 (3) , 54
Assessment and results of early active nutritional interventions during radiotherapy with or without chemotherapy of head-and-neck cancer
Background: Patients of head-and-neck cancer (HANC) undergoing chemoradiotherapy (CRT) are at high risk of malnutrition due to acute effects of radiotherapy (RT). This study was intended to assess weight loss and change in body mass index (BMI) during CRT with active diet counseling and nutritional supplementation. Aims and Objective: The primary end point was to assess loss of weight and BMI during treatment. The secondary end point is assessment of compliance to stipulated treatment time, frequency of nasogastric tube feeding, intravenous support, and duration of hospital admission. Materials and Methods: This was a prospective observational study performed in Radiation Oncology department of a tertiary care center. Consecutive patients of HANC requiring definitive or adjuvant RT (±chemotherapy) were included. Nutritional status assessment and diet counseling were done before start of RT, and further weekly assessment of body weight and BMI was done. Results: Between December 2017 and December 2018, 128 patients were included in this study. Sitewise distribution were oral cavity, oropharynx, hypopharynx, and larynx in 69, 33, 9, and 17 patients, respectively. Weight loss and BMI comparison were done at the start and end of RT (mean weight: 53.86 kg; 95% confidence interval [CI]: ± 1.71, mean BMI: 21.52; 95% CI: ± 0.95 [at the start of RT] and mean weight: 48.30 kg; 95% CI: ± 1.58, mean BMI: 19.18; 95% CI: ± 0.88 [at the end of RT]).There was a significant reduction in weight (P < 0.0001, S) and BMI (P = 0.00034, S), respectively. During the treatment, a total of 14 patients were put on nasogastric tube feeding, and 23 patients were admitted for parenteral nutrition with median hospital stay of 3 days (range: 1–5 days). Conclusions: There is a significant weight loss and change in BMI during CRT in HANC patients. Regular assessment and active nutritional intervention are required in all patients to improve compliance.
- 1 January 2019
- Published by Medknow in Oncology Journal of India
- Vol. 3 (3) , 54
Assessment and results of early active nutritional interventions during radiotherapy with or without chemotherapy of head-and-neck cancer
Background: Patients of head-and-neck cancer (HANC) undergoing chemoradiotherapy (CRT) are at high risk of malnutrition due to acute effects of radiotherapy (RT). This study was intended to assess weight loss and change in body mass index (BMI) during CRT with active diet counseling and nutritional supplementation. Aims and Objective: The primary end point was to assess loss of weight and BMI during treatment. The secondary end point is assessment of compliance to stipulated treatment time, frequency of nasogastric tube feeding, intravenous support, and duration of hospital admission. Materials and Methods: This was a prospective observational study performed in Radiation Oncology department of a tertiary care center. Consecutive patients of HANC requiring definitive or adjuvant RT (±chemotherapy) were included. Nutritional status assessment and diet counseling were done before start of RT, and further weekly assessment of body weight and BMI was done. Results: Between December 2017 and December 2018, 128 patients were included in this study. Sitewise distribution were oral cavity, oropharynx, hypopharynx, and larynx in 69, 33, 9, and 17 patients, respectively. Weight loss and BMI comparison were done at the start and end of RT (mean weight: 53.86 kg; 95% confidence interval [CI]: ± 1.71, mean BMI: 21.52; 95% CI: ± 0.95 [at the start of RT] and mean weight: 48.30 kg; 95% CI: ± 1.58, mean BMI: 19.18; 95% CI: ± 0.88 [at the end of RT]).There was a significant reduction in weight (P < 0.0001, S) and BMI (P = 0.00034, S), respectively. During the treatment, a total of 14 patients were put on nasogastric tube feeding, and 23 patients were admitted for parenteral nutrition with median hospital stay of 3 days (range: 1–5 days). Conclusions: There is a significant weight loss and change in BMI during CRT in HANC patients. Regular assessment and active nutritional intervention are required in all patients to improve compliance.
- 27 March 2018
- Published by Medico Edge Publication in Medico Research Chronicles
- Vol. 5 (2) , 126
Carcinoma of Uterine Cervix with Multiple Skull Metastases as the first Presentation of Recurrence: A Case Report
- 27 March 2018
- Published by Medico Edge Publication in Medico Research Chronicles
- Vol. 5 (2) , 126
Carcinoma of Uterine Cervix with Multiple Skull Metastases as the first Presentation of Recurrence: A Case Report
- Open Access
- 16 March 2017
- Published by PiscoMed Publishing Pte. Ltd. in Advances in Modern Oncology Research
- Vol. 3 (3) , 131-135
An unusual presentation of brain metastasis: Multiple skull and parenchymal lesions masquerading as infective etiology Abstract - 17 PDF - 0
Brain metastasis is a common occurrence in many solid malignancies. The radiological diagnosis is often determined with magnetic resonance imaging (MRI). We report a case of a 60-year-old lady who had headaches for two months, followed by seizures. Her MRI showed multiple skull and brain parenchymal lesions simulating an infective etiology. Further investigations revealed a primary carcinoma of the right lung. The patient showed improvement in symptoms once chemotherapy was started. Brain metastases can masquerade as infective lesions and delay the diagnosis of malignancy. A high index of suspicion is required to allow a prompt diagnosis and treatment.
- 16 March 2017
- Published by PiscoMed Publishing Pte. Ltd. in Advances in Modern Oncology Research
- Vol. 3 (3) , 131-135
Open AccessAn unusual presentation of brain metastasis: Multiple skull and parenchymal lesions masquerading as infective etiology Abstract - 17 PDF - 0
Brain metastasis is a common occurrence in many solid malignancies. The radiological diagnosis is often determined with magnetic resonance imaging (MRI). We report a case of a 60-year-old lady who had headaches for two months, followed by seizures. Her MRI showed multiple skull and brain parenchymal lesions simulating an infective etiology. Further investigations revealed a primary carcinoma of the right lung. The patient showed improvement in symptoms once chemotherapy was started. Brain metastases can masquerade as infective lesions and delay the diagnosis of malignancy. A high index of suspicion is required to allow a prompt diagnosis and treatment.
- 16 December 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (5) , 1439-1443
Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy
Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (50 Gy) with or without chemotherapy. One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly. Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05. Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.
- 16 December 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 25 (5) , 1439-1443
Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy
Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (50 Gy) with or without chemotherapy. One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly. Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05. Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.